Category Archives: Prostate Cell

Prostate Cell News is an online publication and email newsletter summarizing the latest prostate cell research.
Subscribe
Published every week since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.

Prostate Cancer Cell Extracellular Vesicles Increase Mineralization of Bone Osteoblast Precursor Cells in an In Vitro Model

Using osteoblasts as a model system, scientists observed that prostate cancer cells and their conditioned medium could stimulate and increase mineralisation and osteoblasts’ differentiation.
[Biology]
Lanning, B., Webber, J., Uysal-Onganer, P., Jiang, W. G., Clayton, A., & Dart, D. A. (2021). Prostate Cancer Cell Extracellular Vesicles Increase Mineralisation of Bone Osteoblast Precursor Cells in an In Vitro Model. Biology, 10(4), 318. https://doi.org/10.3390/biology10040318 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Kinetics of Radium-223 and Its Effects on Survival, Proliferation and DNA Damage in Lymph-Node and Bone Metastatic Prostate Cancer Cell Lines

Scientists characterized the radiobiological effects induced by Radium-223 and evaluated its kinetics on metastatic prostate cancer cells.
[International Journal of Radiation Biology]
Marques, I. A., Abrantes, A. M., Pires, A. S., Neves, A. R., Caramelo, F. J., Rodrigues, T., Matafome, P., Tavares-da-Silva, E., Gonçalves, A. C., Pereira, C. C., Teixeira, J. P., Seiça, R., Costa, G., Figueiredo, A., & Botelho, M. F. (2021). Kinetics of radium-223 and its effects on survival, proliferation and DNA damage in lymph-node and bone metastatic prostate cancer cell lines. International Journal of Radiation Biology, 0(0), 1–16. https://doi.org/10.1080/09553002.2021.1906462 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Prostate Cancer Study to Be Initiated at Uppsala University Hospital with NanoZolid Technology®

LIDDS AB announced that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy.
[LIDDS AB]
Press Release
Bookmark

No account yet? Register

0
Share

Novel, Non-Invasive Markers for Detecting Therapy Induced Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer Patients

Scientists identified novel, extracellular vesicles-based biomarkers for diagnosing neuroendocrine prostate cancer.
[Scientific Reports]
Bhagirath, D., Liston, M., Akoto, T., Lui, B., Bensing, B. A., Sharma, A., & Saini, S. (2021). Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients. Scientific Reports, 11(1), 8279. https://doi.org/10.1038/s41598-021-87441-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

PROCEPT® BioRobotics Announces Growing Coverage for Aquablation Therapy for Patients with Enlarged Prostate

PROCEPT® BioRobotics Corporation announced that Blue Cross Blue Shield of Massachusetts and EmblemHealth are now providing insurance coverage for Aquablation therapy delivered by the AquaBeam® Robotic System for the treatment of benign prostatic hyperplasia
[PROCEPT® BioRobotics Corporation]
Press Release
Bookmark

No account yet? Register

0
Share

A Cyclometalated IrIII Complex Conjugated to a Coumarin Derivative Is a Potent Photodynamic Agent against Prostate Differentiated and Tumorigenic Cancer Stem Cells

The authors showed. using DU145 tumor cells, taken as the model of hormone‐refractory and aggressive prostate cancer cells resistant to conventional antineoplastic drugs, that the photoactivated 3 very efficiently eliminated both prostate bulk, differentiated and prostate, hardly treatable cancer stem cells simultaneously and with a similar efficiency.
[Chemistry-A European Journal]
Novohradsky, V., Markova, L., Kostrhunova, H., Kasparkova, J., Ruiz, J., Marchán, V., & Brabec, V. (n.d.). A Cyclometalated IrIII Complex Conjugated to a Coumarin Derivative Is a Potent Photodynamic Agent against Prostate Differentiated and Tumorigenic Cancer Stem Cells. Chemistry – A European Journal, n/a(n/a). https://doi.org/https://doi.org/10.1002/chem.202100568 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Synthesis and Evaluation of Tumor-Homing Peptides for Targeting Prostate Cancer

Researchers determined which prostate-specific membrane antigen (PSMA)-binding peptide among peptides 563, 562 and 9-mer, showed the highest selectivity towards PSMA using 22Rv1 prostate cancer cells, a cell line with moderate PSMA levels.
[Amino Acids]
Nezir, A. E., Khalily, M. P., Gulyuz, S., Ozcubukcu, S., Küçükgüzel, Ş. G., Yilmaz, O., & Telci, D. (2021). Synthesis and evaluation of tumor-homing peptides for targeting prostate cancer. Amino Acids. https://doi.org/10.1007/s00726-021-02971-3 Cite
Abstract
Bookmark

No account yet? Register

0
Share

PRMT5: A Putative Oncogene and Therapeutic Target in Prostate Cancer

The authors focus on recent progress made in prostate cancer, including the role of protein arginine methyltransferase 5 (PRMT5) in the androgen receptor expression and signaling and DNA damage response, particularly DNA double-strand break repair.
[Cancer Gene Therapy]
Beketova, E., Owens, J. L., Asberry, A. M., & Hu, C.-D. (2021). PRMT5: a putative oncogene and therapeutic target in prostate cancer. Cancer Gene Therapy, 1–13. https://doi.org/10.1038/s41417-021-00327-3 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Targeting KDM1B-Dependent miR-215-AR-AGR2-Axis Promotes Sensitivity to Enzalutamide-Resistant Prostate Cancer

Downregulation of miR-215 was correlated with overexpression of KDM1B in enzalutamide-resistant prostate cancer cells, which promoted AR-dependent AGR2 transcription and regulated the sensitivity to next generation AR-targeted therapy.
[Cancer Gene Therapy]
Tang, D., He, J., Dai, Y., Geng, X., Leng, Q., Jiang, H., Sun, R., & Xu, S. (2021). Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer. Cancer Gene Therapy, 1–15. https://doi.org/10.1038/s41417-021-00332-6 Cite
Abstract
Bookmark

No account yet? Register

0
Share

CDC2-Like (CLK) Protein Kinase Inhibition as a Novel Targeted Therapeutic Strategy in Prostate Cancer

Scientists measured the effect of the CLK inhibitor, the benzothiazole TG003, on two prostate cancer cell lines. TG003 reduced cell proliferation and increased apoptosis in PC3 and DU145 cells.
[Scientific Reports]
Uzor, S., Porazinski, S. R., Li, L., Clark, B., Ajiro, M., Iida, K., Hagiwara, M., Alqasem, A. A., Perks, C. M., Wilson, I. D., Oltean, S., & Ladomery, M. R. (2021). CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific Reports, 11(1), 7963. https://doi.org/10.1038/s41598-021-86908-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Aberrant CREB1 Activation in Prostate Cancer Disrupts Normal Prostate Luminal Cell Differentiation

Researchers discovered that CREB1 played a central role in maintaining new luminal cell survival and that oncogenesis dramatically changed the CREB1-induced transcriptome. CREB1 was active in luminal cells, but not basal cells.
[Oncogene]
Watson, M. J., Berger, P. L., Banerjee, K., Frank, S. B., Tang, L., Ganguly, S. S., Hostetter, G., Winn, M., & Miranti, C. K. (2021). Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation. Oncogene, 1–13. https://doi.org/10.1038/s41388-021-01772-y Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share